Literature DB >> 1315288

Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes.

C Negri1, R Chiesa, A Cerino, M Bestagno, C Sala, N Zini, N M Maraldi, G C Astaldi Ricotti.   

Abstract

Several monoclonal antibodies of different isotypes specific to human DNA topoisomerase I, to 170- and 180-kDa DNA topoisomerase II isozymes, were produced and characterized. The specificity of monoclonal antibodies was confirmed by comparison with polyclonal antibodies by Western blot, by immunoprecipitation of enzyme activity, and by immunoprecipitation of DNA topoisomerases with characterized polyclonal antisera. Morphological studies performed by immunofluorescence indicate that the three groups of monoclonal antibodies (MoAbs) stain the nucleus with characteristic patterns, which can be compared with those obtained with polyclonal antibodies. In particular the MoAbs to the 100-kDa DNA topoisomerase I stain the nucleolus and the nucleoplasm; the MoAbs to 170- and 180-kDa DNA topoisomerase II give completely distinct intranuclear patterns: those to the 170-kDa protein stain mainly the nucleoplasm, whereas those to the 180-kDa protein stain only the nucleolus. The two DNA topoisomerase II isozymes clearly exhibit fluctuations in their expression during cell growth: the 170-kDa isozyme is more abundant during the logarithmic phase of growth, while the 180-kDa isozyme is mainly present during the plateau phase of growth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315288     DOI: 10.1016/0014-4827(92)90195-e

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  27 in total

1.  Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.

Authors:  J H Yoon; J K Kim; G B Rha; M Oh; S H Park; R H Seong; S H Hong; S D Park
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

3.  Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.

Authors:  N Adachi; M Miyaike; S Kato; R Kanamaru; H Koyama; A Kikuchi
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

4.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

5.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

6.  In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

7.  The distribution of topoisomerase II on mammalian chromosomes.

Authors:  A T Sumner
Journal:  Chromosome Res       Date:  1996-01       Impact factor: 5.239

8.  Organization of DNA topoisomerase II isotypes during the cell cycle of human lymphocytes and HeLa cells.

Authors:  N Chaly; X Chen; J Dentry; D L Brown
Journal:  Chromosome Res       Date:  1996-09       Impact factor: 5.239

9.  Human cells express two differentially spliced forms of topoisomerase II beta mRNA.

Authors:  S L Davies; J R Jenkins; I D Hickson
Journal:  Nucleic Acids Res       Date:  1993-08-11       Impact factor: 16.971

10.  DNA-AP sites generation by etoposide in whole blood cells.

Authors:  Emilio Rojas; Patricia Mussali; Efrain Tovar; Mahara Valverde
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.